Skip to content

Microdosing

The practice of taking sub-perceptual doses of psychedelics, and the evidence on whether measurable effects follow.

State of the evidence

Synthesized

Synthesized from 17 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Microdosing, micro-dosing, sub-perceptual dosing, low-dose psychedelics, then ranked by relevance.

Placebo-controlled and blinded studies consistently find that psychedelic microdosing does not produce significant improvements in mood, well-being, or cognition beyond placebo, with the only significant pooled effect being a small decrease in cognitive control. Observational and survey studies report subjective benefits, but these are likely explained by expectancy and placebo effects. The main caveat is that most positive evidence comes from uncontrolled or open-label designs, and the controlled evidence base remains limited in size and duration.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 17 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Self-blinding citizen science to explore psychedelic microdosing. 2021
No effect

No significant between-group differences were found between microdose and placebo on psychological outcomes, suggesting anecdotal benefits are due to the placebo effect.

self-blinding citizen science initiative with placebo control Sample size: 191

Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting 2018
Supports

This open-label study found quantitative support for cognitive-enhancing properties of microdosing psychedelics, speculating that psychedelics optimize the balance between cognitive persistence and flexibility.

preliminary study

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers 2019
Supports

Current and former microdosers scored lower on dysfunctional attitudes and negative emotionality and higher on wisdom, open-mindedness, and creativity compared to non-microdosing controls.

observational study

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing 2021
Mixed

Improvements in well-being and mood were observed, but positive expectancy at baseline predicted these improvements, indicating a significant placebo response.

prospective observational study Sample size: 81

Motives and Side-Effects of Microdosing With Psychedelics Among Users 2019
Mixed

Performance enhancement was the main motive for microdosing, but the most common reason for stopping was lack of effectiveness, and negative effects were mostly acute and psychological.

cross-sectional survey Sample size: 1116

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study 2022
No effect

Low doses of psilocybin produced noticeable subjective effects and altered EEG rhythms but did not enhance well-being, creativity, or cognitive function, indicating that expectation underlies many reported benefits.

double-blind placebo-controlled experimental design Sample size: 34

Psychedelic microdosing benefits and challenges: an empirical codebook 2019
Supports

Participant reports from the microdosing community were summarized into a taxonomy of high-potential intervention targets for future research.

mixed-methods study

Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. 2019
Supports

Spaced but repeated microdoses of LSD were followed by improvements in negative moods, especially depression, and increases in positive moods.

observational cohort Sample size: 1000

Psychedelic Microdosing: A Subreddit Analysis 2019
Mixed

Self-reported benefits included cognitive and creative enhancement and reduced depression and anxiety, but limitations included adverse physical effects and concerns about dependence.

content analysis

Microdosing psychedelics: Motivations, subjective effects and harm reduction 2019
Supports

Microdosing was primarily used as a self-managed therapy for mental health, with perceived short-term benefits including improved mood and anxiety, enhanced connection, and cognitive enhancement.

cross-sectional survey Sample size: 525

Psychedelic Microdosing: Prevalence and Subjective Effects 2020
Supports

Microdosers attributed psychedelic microdosing with improving mood, decreasing anxiety, and enhancing memory, attention, and sociability.

cross-sectional survey Sample size: 2347

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026
No effect

Chronic psilocin microdosing did not affect locomotor activity, depressive-like behavior, sociability, or novelty seeking, and did not increase dentate gyrus cell proliferation, though a small anxiogenic effect was observed.

preclinical experimental study

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis 2026
Mixed

The only significant pooled effect was a small decrease in cognitive control; mood benefits were not replicated under placebo-controlled conditions.

umbrella review with narrative synthesis Sample size: 1614

Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States 2026
Unclear

Mental health symptoms and adverse childhood events were associated with psychedelic use, microdosing, and higher use motives, even among those using exclusively for nonmedical purposes.

cross-sectional survey Sample size: 1614

Beyond Psychedelic Microdosing: Therapeutic Potential, Neuropharmacology, and Safety Considerations in Low-Dose Psychoactive Use 2026
Unclear

Argues that microdosing research must classify substances by mechanism, dose-response, perceptibility, context, and evidence strength to produce interpretable scientific conclusions.

conceptual and comparative review

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series 2026
Supports

All three participants showed progressive neurological recovery after a six-week integrative iboga microdosing protocol with psychotherapy, with two achieving complete symptom remission at long-term follow-up.

case series Sample size: 3

U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey. 2026
Unclear

Reports that microdosing psilocybin, LSD, and MDMA is a prevalent practice among users of psychedelic substances, providing data to inform policy discussions.

survey

Points of agreement

  • Placebo-controlled and blinded studies consistently find no significant benefits of psychedelic microdosing on mood, well-being, or cognition compared to placebo.
  • Observational and survey studies consistently report subjective improvements in mood, anxiety, and cognition among microdosers.
  • Expectancy and placebo effects are widely identified as likely explanations for the perceived benefits of microdosing.

Conflicts

  • Observational and open-label studies report positive effects on mood and cognition, whereas placebo-controlled trials find no significant differences.
  • Some studies report cognitive enhancement, while an umbrella review found a small decrease in cognitive control.

Gaps

  • Most positive evidence comes from uncontrolled or open-label designs, lacking rigorous blinding and placebo control.
  • Long-term effects and durability of any benefits are not well studied.
  • Diverse substances, doses, and schedules are used, making comparisons difficult.
  • Few studies include diverse or clinical populations; many rely on self-selected online samples.
  • The role of expectancy is not fully controlled in most studies.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Microdosing, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Microdosing or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: June 2026 →

490 articles · 190 from the last two years · 92,182 participants across 182 studies reporting sample size

Common study designs

review 97 qualitative study 22 cross-sectional survey 21 randomized controlled trial 39 theoretical or philosophical paper 23

Research

Synthesize the evidence → Search all →

Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis

Zenodo (CERN European Organization for Nuclear Research) September 2, 2026 Andrea Vittorini

This hypothesis and perspective article proposes that uninterrupted daily low-dose psilocybin may constitute a pharmacologically distinct receptor-adaptation paradigm. Repeated 5-HT2A agonist pulses could progressively produce functional desensitization, internalization, and/or down-regulation; the fading of acute subjective effects may therefore mark the development of an adaptive state rather...

DOI: 10.5281/zenodo.22239349 (opens in new tab)

230. LSD microdosing for depression: hype or hope? A randomised controlled trial in major depressive disorder

International Journal of Neuropsychopharmacology September 1, 2026

Abstract Background Depressive disorders affect approximately 280 million people worldwide, with many patients finding existing treatments ineffective or limited by adverse effects. Growing evidence from community microdosing reports suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing has shown particular promise...

DOI: 10.1093/ijnp/pyag040.021 (opens in new tab) Full text (opens in new tab)

COMBINED MICRODOSING OF NPK AND UREA: EFFECTS ON PRODUCTIVITY AND ECONOMIC PROFITABILITY OF SESAME (SESAMUM INDICUM L.) IN SEMI-ARID BURKINA FASO

International Journal of Advanced Research August 31, 2026 Ouedraogo Jean, Sawadogo Achille, Nignan Iliassou et al.

The combined microdose of NPK and urea could be a sustainable intensification strategy for sesame cultivation in semi-arid areas of West Africa.This study evaluated the effects of different NPK microdose treatments, both alone and in combination with urea, on sesame productivity and economic profitability in the North Sudanese zone of Burkina Faso.The trial was conducted in 2019 and 2020 at the...

DOI: 10.21474/ijar01/24066 (opens in new tab)

Endogenous honeycomb stone arrangements reduce soil erosion, improve soil moisture, and sorghum productivity under fertilizer microdosing on steep lands of Boukombé in northwestern Benin

Discover Soil August 30, 2026 R. Lokossou, P. B. Irénikatché Akponikpè, Fidèle T. Moutouama et al.

The biophysical field-based evaluation of the endogenous soil and water conservation (SWC) practices in the hilly region of sub-Saharan West Africa is lacking. To address this, the current study aims to evaluate the most commonly used erosion control practices in the hilly region of Boukombé through a rainfed field experiment conducted under sorghum over two growing seasons (2012–2013) on a...

DOI: 10.1007/s44378-026-00301-1 (opens in new tab) Full text (opens in new tab)

The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing

Frontiers in Psychiatry August 19, 2026 Jeni Page, Alexandra Moore, Bridget E. Hawkins et al.

IntroductionMicrodosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing...

DOI: 10.3389/fpsyt.2026.1866881 (opens in new tab) Full text (opens in new tab) Magic mushrooms Microdosing Psilocybin Psychedelic substances +1

Effect of fertilizer Microdosing of and Microbial Inoculation on Pearl Millet ( Pennisetum glaucum (L.) R. Br) Growth on Two Soils of the Peanut Basin of Senegal

International Journal of Applied Agricultural Sciences July 3, 2026 Khady Diaw, Ramatoulaye Samba, Malick Ndiaye et al.

Pearl millet ( Pennisetum glaucum (L.) R. Br) is a very important cereal crop in the semi-arid regions of West Africa, serving as a primary food source for local populations. Therefore, its productivity remains lowered by soil degradation and low availability of inputs as fertilizers. In this context, biofertilizers and organic amendments offer sustainable and ecological alternatives for...

DOI: 10.11648/j.ijaas.20261204.11 (opens in new tab) Pennisetum Randomized block design Biofertilizer Crop +10

Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.

Cureus July 2026 Mia A Panlilio, Natalie Piserchio, Mercedes Hennessey et al.

Glucagon-like peptide-1 (GLP-1) is an endocrine hormone that plays a role in lowering blood glucose levels and promoting weight loss. GLP-1 receptor agonists (GLP-1 RAs) are synthetic peptides that mimic the activity of GLP-1, and the recent development of GLP-1 RA medications has been a major historical advancement in the treatment of diabetes and obesity. Despite the rapid development of...

DOI: 10.7759/cureus.113635 (opens in new tab) Full text (opens in new tab) Microdosing Glp-1 agonists Metabolism Obesity +2

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, biochemistry, and behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

DOI: 10.1016/j.pbb.2026.174231 (opens in new tab) Full text (opens in new tab) Anxiety Depression Behavioral testing Hippocampal neurogenesis +3

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis

Journal of Psychopharmacology June 28, 2026 Yiğit Özaydın, Buket Canlan Özaydın

Background: Psychedelic microdosing—repeated sub-perceptual doses of lysergic acid diethylamide (LSD) or psilocybin—has attracted scientific interest as a potential mood and cognitive intervention. The evidence base remains methodologically heterogeneous and vulnerable to expectancy bias. Methods: We conducted an umbrella review with narrative synthesis following Joanna Briggs Institute...

DOI: 10.1177/02698811261456196 (opens in new tab) Psilocybin Mood Cognition Expectancy theory +6

Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States

Journal of Psychoactive Drugs June 19, 2026 Carla J. Berg, Darcey M. Mccready, Cassidy R Loparco et al.

= 26.38, ~50% past-month cannabis use by design) completed an online survey. Multivariable regression assessed sociodemographics, mental health, and adverse childhood events (ACEs) in relation to: (1) past-year psychedelic use; and (2) among those reporting lifetime use: (a) lifetime microdosing and (b) use motives. Lifetime and past-year psychedelic use were 27.7% and 11.9% (commonly...

DOI: 10.1080/02791072.2026.2685527 (opens in new tab) Addiction Young adult Product mathematics Substance use +1

Clinical trials

All Microdosing trials →